H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on COYA stock, giving a Buy rating today.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ram Selvaraju has given his Buy rating due to a combination of factors, including the recent expansion of Coya Therapeutics’ patent estate. The issuance of a U.S. patent covering stable liquid formulations of interleukin-2 (IL-2) strengthens the company’s intellectual property portfolio, providing exclusive rights for various therapeutic applications. This development is expected to bolster Coya’s position in the market and enhance its potential for future growth.
Additionally, several upcoming catalysts contribute to the positive outlook for Coya Therapeutics. These include the anticipated data submissions for COYA 301/GLP-1 and COYA-302, potential milestone payments from strategic partnerships, and the release of clinical data from ongoing trials. The company’s progress in its Treg-derived exosome program and alignment with the FDA on trial requirements further support the Buy rating. However, Selvaraju also notes potential risks, such as clinical setbacks and regulatory challenges, which investors should consider.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 16.5% and a 48.28% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Anavex Life Sciences, and Axsome Therapeutics.
In another report released today, Lucid Capital also initiated coverage with a Buy rating on the stock with a $20.00 price target.